IL245045B - Selective pyy compounds and their uses - Google Patents

Selective pyy compounds and their uses

Info

Publication number
IL245045B
IL245045B IL245045A IL24504516A IL245045B IL 245045 B IL245045 B IL 245045B IL 245045 A IL245045 A IL 245045A IL 24504516 A IL24504516 A IL 24504516A IL 245045 B IL245045 B IL 245045B
Authority
IL
Israel
Prior art keywords
pyy compounds
selective
selective pyy
compounds
pyy
Prior art date
Application number
IL245045A
Other languages
English (en)
Hebrew (he)
Other versions
IL245045A0 (en
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL245045A0 publication Critical patent/IL245045A0/en
Publication of IL245045B publication Critical patent/IL245045B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IL245045A 2013-11-15 2016-04-11 Selective pyy compounds and their uses IL245045B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13193082 2013-11-15
US201361906020P 2013-11-19 2013-11-19
EP14176725 2014-07-11
PCT/EP2014/074476 WO2015071355A1 (en) 2013-11-15 2014-11-13 Selective pyy compounds and uses thereof

Publications (2)

Publication Number Publication Date
IL245045A0 IL245045A0 (en) 2016-05-31
IL245045B true IL245045B (en) 2019-09-26

Family

ID=53056816

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245045A IL245045B (en) 2013-11-15 2016-04-11 Selective pyy compounds and their uses

Country Status (15)

Country Link
US (2) US9085637B2 (enExample)
EP (1) EP3068421B1 (enExample)
JP (1) JP6602760B2 (enExample)
KR (1) KR20160075819A (enExample)
CN (1) CN105722526B (enExample)
AU (1) AU2014350197B2 (enExample)
BR (1) BR112016010383A2 (enExample)
CA (1) CA2929672A1 (enExample)
IL (1) IL245045B (enExample)
MX (1) MX369818B (enExample)
PL (1) PL3068421T3 (enExample)
RS (1) RS59026B1 (enExample)
SI (1) SI3068421T1 (enExample)
TW (1) TWI661835B (enExample)
WO (1) WO2015071355A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
CN105263957A (zh) * 2013-05-02 2016-01-20 葛兰素史克知识产权开发有限公司 治疗肽
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
CA2929672A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
TWI694082B (zh) * 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
HRP20221150T1 (hr) * 2016-04-28 2022-11-25 Novo Nordisk A/S Semaglutid u kardiovaskularnim stanjima
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
US20200165313A1 (en) 2017-07-19 2020-05-28 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof
CN118903386A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
US20210171598A1 (en) 2017-12-01 2021-06-10 University Of Copenhagen Peptide hormone with one or more o-glycans
CN112055592A (zh) * 2018-01-09 2020-12-08 吉拉毒蜥治疗公司 用于治疗代谢疾病的组合物和方法
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
TWI865836B (zh) * 2018-11-01 2024-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
JP2022543826A (ja) * 2019-08-07 2022-10-14 ノヴォ ノルディスク アー／エス Ｐｙｙ化合物とｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
MX2022005661A (es) * 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
PE20231566A1 (es) 2020-08-07 2023-10-04 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
CA3197916A1 (en) * 2020-11-09 2022-05-12 Magnus Bernt Fredrik Gustafsson Compounds and their use in treatment of tachykinin receptor mediated disorders
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
WO2025128624A2 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent
WO2025128626A1 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a modified lysine residue

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
CN1311773A (zh) 1998-06-08 2001-09-05 先灵公司 神经肽y5受体拮抗剂
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP2123293A3 (en) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP2277527A3 (en) 2003-01-17 2011-08-31 Ipsen Pharma Peptide YY analogs
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CN1893980A (zh) 2003-12-18 2007-01-10 诺沃挪第克公司 与白蛋白样物质相连的新glp－1类似物
RU2378285C2 (ru) 2004-02-11 2010-01-10 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
EP2335716A3 (en) 2004-02-11 2011-10-19 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP2272524A3 (en) 2004-03-17 2011-02-02 7TM Pharma A/S Y2 selective receptor agonists for therapeutic interventions
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
CA2560166A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
CN1933848A (zh) 2004-03-17 2007-03-21 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006005667A2 (en) 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
KR20080033392A (ko) 2005-07-11 2008-04-16 나스텍 파마수티컬 컴퍼니 인코포레이티드 펩타이드 ｙｙ의 향상된 점막 전달을 위한 제형들
US20090203581A1 (en) 2005-07-18 2009-08-13 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
CA2623094A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
WO2007038942A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
EP1962959B1 (en) 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Neuropeptide-2 receptor-agonists
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2101822A2 (en) 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
US20100279930A1 (en) 2007-07-09 2010-11-04 Stephen Robert Bloom Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
CN101842109B (zh) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
WO2009043477A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
KR20110017874A (ko) 2008-05-16 2011-02-22 노보 노르디스크 에이/에스 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
KR20110097807A (ko) * 2008-11-05 2011-08-31 에프. 호프만-라 로슈 아게 뉴로펩티드-2-수용체(ｙ-2ｒ) 작용제 및 이의 용도
EP2398492A4 (en) 2009-02-20 2013-07-17 Ipsen Pharma Sas CYTOTOXIC CONJUGATES HAVING NEUROPEPTIDE Y RECEPTOR BINDING COMPOUND
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
EP2488195A2 (en) 2009-10-13 2012-08-22 F. Hoffmann-La Roche AG Neuropeptide-2 receptor (y-2r) agonists
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011131646A1 (en) 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
KR101927068B1 (ko) * 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
CN105263957A (zh) 2013-05-02 2016-01-20 葛兰素史克知识产权开发有限公司 治疗肽
CA2929672A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
TWI694082B (zh) * 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途

Also Published As

Publication number Publication date
AU2014350197A1 (en) 2016-05-05
US9085637B2 (en) 2015-07-21
WO2015071355A1 (en) 2015-05-21
US20150152150A1 (en) 2015-06-04
CN105722526B (zh) 2020-12-08
MX369818B (es) 2019-11-22
KR20160075819A (ko) 2016-06-29
IL245045A0 (en) 2016-05-31
JP2017505284A (ja) 2017-02-16
TWI661835B (zh) 2019-06-11
EP3068421B1 (en) 2019-04-17
CN105722526A (zh) 2016-06-29
BR112016010383A2 (pt) 2017-12-05
EP3068421A1 (en) 2016-09-21
CA2929672A1 (en) 2015-05-21
MX2016006053A (es) 2016-08-17
JP6602760B2 (ja) 2019-11-06
US20160289283A1 (en) 2016-10-06
SI3068421T1 (sl) 2019-08-30
AU2014350197B2 (en) 2018-10-04
RS59026B1 (sr) 2019-08-30
US10246497B2 (en) 2019-04-02
PL3068421T3 (pl) 2019-11-29
TW201605467A (zh) 2016-02-16

Similar Documents

Publication Publication Date Title
IL274355B (en) Aza-pyridone compounds and their uses
IL276113B (en) Electronic smoking part and electronic smoking device
IL245045B (en) Selective pyy compounds and their uses
DK3088517T5 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
IL240275B (en) Selective antisense compounds and their uses
ZA201603549B (en) New pesticidal compounds and uses
GB201323008D0 (en) Compounds and uses thereof
GB201317802D0 (en) SmartHaler patent application
IL240248A0 (en) Met-binding substances and their uses
GB201300707D0 (en) Compounds and processes
IL244214A0 (en) Thienopiperidine derivative and its use
GB201307233D0 (en) Compounds and uses thereof
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201309180D0 (en) Compounds and Their Uses
GB201301329D0 (en) Fluidfoil
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
HUE043900T2 (hu) Szelektív PYY vegyületek és alkalmazásuk
AU5373P (en) Sungelobu Angelonia angustifolia
AU5374P (en) Sungelodepi Angelonia angustifolia
AU5375P (en) Sungeloho Angelonia angustifolia
GB201309248D0 (en) Compounds and combinations
GB201323005D0 (en) Compounds and uses thereof
AU4977P (en) Harrosy Gaura lindheimeri

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees